Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT) is an integral membrane enzyme that catalyzes the final and only committed step in the biosynthesis of triacylglycerol (TAG). There are two main isoforms in mammals, DGAT1 and DGAT2. DGAT plays a central role in cellular glycerolipid metabolism and is essential for physiological processes such as intestinal fat absorption, lipoprotein assembly, adipose tissue formation, and lactation. Disruption or inhibition of these enzymes affects lipid droplet formation, fatty acid oxidation rates, lipogenic gene expression, and overall lipid homeostasis—making them potential therapeutic targets for obesity, diabetes mellitus type II, dyslipidemia/metabolic syndrome, atherosclerosis/cardiovascular disease.
Inhibition of DGAT1 or DGAT2 reduces triacylglycerol synthesis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT).